Pharma Stock Jumps 5% After Announcing Acquisition of Nasdaq-Listed Pharma Firm for ₹1,600 Cr

Synopsis: A leading pharma group expands its US specialty oncology footprint through an all-cash buyout of a Nasdaq-listed firm with an approved cancer supportive-care drug.

The Indian pharmaceutical sector has been steadily building its presence in high-value specialty segments in the United States, with oncology emerging as a key battleground. One of the country’s larger drug makers has now taken a significant step in that direction, signing a definitive agreement to fully acquire a US-listed oncology-focused company in an all-cash deal worth over $166 million.

With a market cap of Rs. 99,573 Crore, the shares of Zydus Lifesciences Ltd. are trading at a price of Rs. 989 per share i.e. 5.3% up from its previous closing price of Rs. 939.25. It currently trades at P/E of 19.5.

Zydus Eyes US Oncology With Around Rs. 1600 Crore Assertio Buyout

Zydus Lifesciences Limited announced on May 13, 2026, that its subsidiary Zydus Worldwide DMCC has signed a definitive agreement to acquire all outstanding shares of Assertio Holdings, Inc. at USD 23.50 per share in cash. 

The total consideration stands at approximately USD 166.4 million i.e. around Rs.1,600 crore on a fully-diluted basis, calculated using the treasury stock method. The announcement sent the stock up 5% as investors cheered the company’s push into the US specialty oncology market.

The transaction will be executed through Zara Merger Sub Inc., a wholly owned acquisition subsidiary, and is structured as a tender offer followed by a merger. Once the tender offer closes – expected within five business days of the agreement date – Zydus will acquire any remaining shares not tendered through a second-step merger at the same price. 

Assertio will be delisted from Nasdaq upon successful completion of the deal. The transaction is expected to close in FY2026-27, subject to customary regulatory approvals and conditions, including the tender of a majority of Assertio’s outstanding shares.

A Ready-Made Oncology Platform

The key attraction of this deal is Assertio’s flagship product ROLVEDON® (eflapegrastim-xnst), a long-acting G-CSF biologic approved by the USFDA under a Biologics License Application (BLA) for the prevention of febrile neutropenia in adult cancer patients undergoing myelosuppressive chemotherapy. 

The drug is administered once per chemotherapy cycle, giving it a practical edge in the oncology supportive care market. Adjusted turnover for ROLVEDON® grew from USD 18.18 million in CY2023 (five months, post-July 2023 acquisition by Assertio) to USD 60.09 million in CY2024, and further to USD 68.23 million in CY2025, reflecting strong commercial momentum.

Assertio’s network of 170+ community oncology accounts and its buy-and-bill distribution infrastructure gives Zydus what the company describes as a “ready-made” base to build a broader oncology specialty portfolio in the US – a market that Zydus has been targeting as part of its long-term strategy.

Speaking on the deal, Dr. Sharvil P. Patel, Managing Director, Zydus Lifesciences, said the transaction strengthens the company’s specialty and oncology presence in the US and aligns with its objective of building differentiated, durable specialty businesses globally.

About Zydus Lifesciences Limited 

Zydus Lifesciences Limited is an innovation-led global lifesciences company engaged in the discovery, development, manufacturing, and marketing of a wide range of healthcare therapies. The group employs over 29,000 people worldwide, including 1,500 R&D scientists, and has introduced several first-in-class products across vaccines, biologicals, therapeutics, and new chemical entities over the past decade.

Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.in are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Trade Brains Technologies Private Limited or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing.

The post Pharma Stock Jumps 5% After Announcing Acquisition of Nasdaq-Listed Pharma Firm for ₹1,600 Cr appeared first on Trade Brains.